A2 Refereed review article in a scientific journal
Native T-1 reference values for nonischemic cardiomyopathies and populations with increased cardiovascular risk: A systematic review and meta-analysis
Authors: van den Boomen M, Slart RHJA, Hulleman EV, Dierckx RAJO, Velthuis BK, van der Harst P, Sosnovik DE, Borra RJH, Prakken NHJ
Publisher: WILEY
Publication year: 2018
Journal: Journal of Magnetic Resonance Imaging
Journal name in source: JOURNAL OF MAGNETIC RESONANCE IMAGING
Journal acronym: J MAGN RESON IMAGING
Volume: 47
Issue: 4
First page : 891
Last page: 912
Number of pages: 22
ISSN: 1053-1807
DOI: https://doi.org/10.1002/jmri.25885
Abstract
BackgroundAlthough cardiac MR and T-1 mapping are increasingly used to diagnose diffuse fibrosis based cardiac diseases, studies reporting T-1 values in healthy and diseased myocardium, particular in nonischemic cardiomyopathies (NICM) and populations with increased cardiovascular risk, seem contradictory.PurposeTo determine the range of native myocardial T-1 value ranges in patients with NICM and populations with increased cardiovascular risk.Study TypeSystemic review and meta-analysis.PopulationPatients with NICM, including hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM), and patients with myocarditis (MC), iron overload, amyloidosis, Fabry disease, and populations with hypertension (HT), diabetes mellitus (DM), and obesity.Field Strength/Sequence(Shortened) modified Look-Locker inversion-recovery MR sequence at 1.5 or 3T.AssessmentPubMed and Embase were searched following the PRISMA guidelines.Statistical TestsThe summary of standard mean difference (SMD) between the diseased and a healthy control populations was generated using a random-effects model in combination with meta-regression analysis.ResultsThe SMD for HCM, DCM, and MC patients were significantly increased (1.41, 1.48, and 1.96, respectively, P < 0.01) compared with healthy controls. The SMD for HT patients with and without left-ventricle hypertrophy (LVH) together was significantly increased (0.19, P=0.04), while for HT patients without LVH the SMD was zero (0.03, P=0.52). The number of studies on amyloidosis, iron overload, Fabry disease, and HT patients with LVH did not meet the requirement to perform a meta-analysis. However, most studies reported a significantly increased T-1 for amyloidosis and HT patients with LVH and a significant decreased T-1 for iron overload and Fabry disease patients.Data ConclusionsNative T-1 mapping by using an (Sh)MOLLI sequence can potentially assess myocardial changes in HCM, DCM, MC, iron overload, amyloidosis, and Fabry disease compared to controls. In addition, it can help to diagnose left-ventricular remodeling in HT patients. Level of Evidence: 2 Technical Efficacy: Stage 3 J. Magn. Reson. Imaging 2018;47:891-912.
BackgroundAlthough cardiac MR and T-1 mapping are increasingly used to diagnose diffuse fibrosis based cardiac diseases, studies reporting T-1 values in healthy and diseased myocardium, particular in nonischemic cardiomyopathies (NICM) and populations with increased cardiovascular risk, seem contradictory.PurposeTo determine the range of native myocardial T-1 value ranges in patients with NICM and populations with increased cardiovascular risk.Study TypeSystemic review and meta-analysis.PopulationPatients with NICM, including hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM), and patients with myocarditis (MC), iron overload, amyloidosis, Fabry disease, and populations with hypertension (HT), diabetes mellitus (DM), and obesity.Field Strength/Sequence(Shortened) modified Look-Locker inversion-recovery MR sequence at 1.5 or 3T.AssessmentPubMed and Embase were searched following the PRISMA guidelines.Statistical TestsThe summary of standard mean difference (SMD) between the diseased and a healthy control populations was generated using a random-effects model in combination with meta-regression analysis.ResultsThe SMD for HCM, DCM, and MC patients were significantly increased (1.41, 1.48, and 1.96, respectively, P < 0.01) compared with healthy controls. The SMD for HT patients with and without left-ventricle hypertrophy (LVH) together was significantly increased (0.19, P=0.04), while for HT patients without LVH the SMD was zero (0.03, P=0.52). The number of studies on amyloidosis, iron overload, Fabry disease, and HT patients with LVH did not meet the requirement to perform a meta-analysis. However, most studies reported a significantly increased T-1 for amyloidosis and HT patients with LVH and a significant decreased T-1 for iron overload and Fabry disease patients.Data ConclusionsNative T-1 mapping by using an (Sh)MOLLI sequence can potentially assess myocardial changes in HCM, DCM, MC, iron overload, amyloidosis, and Fabry disease compared to controls. In addition, it can help to diagnose left-ventricular remodeling in HT patients. Level of Evidence: 2 Technical Efficacy: Stage 3 J. Magn. Reson. Imaging 2018;47:891-912.
UTU Research Portal